Corrigendum to “Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181” [The Journal of Prevention of Alzheimer's Disease (2026) 100664]

Moeko Noguchi-Shinohara, Daiki Muramatsu, Ayano Shima, Yasuhiro Sakashita, Yasutake Tada, Hiroki Yamaguchi, Junji Komatsu, Tokuhei Ikeda, Kenjiro Ono

Open source

DOI
10.1016/j.tjpad.2026.100668
Published
2026-11
Container
The Journal of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2026.100668,
  title = {Corrigendum to “Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181” [The Journal of Prevention of Alzheimer's Disease (2026) 100664]},
  author = {Moeko Noguchi-Shinohara and Daiki Muramatsu and Ayano Shima and Yasuhiro Sakashita and Yasutake Tada and Hiroki Yamaguchi and Junji Komatsu and Tokuhei Ikeda and Kenjiro Ono},
  year = {2026},
  journal = {The Journal of Prevention of Alzheimer's Disease},
  doi = {10.1016/j.tjpad.2026.100668},
  url = {https://doi.org/10.1016/j.tjpad.2026.100668}
}

RIS

TY  - JOUR
TI  - Corrigendum to “Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181” [The Journal of Prevention of Alzheimer's Disease (2026) 100664]
AU  - Moeko Noguchi-Shinohara
AU  - Daiki Muramatsu
AU  - Ayano Shima
AU  - Yasuhiro Sakashita
AU  - Yasutake Tada
AU  - Hiroki Yamaguchi
AU  - Junji Komatsu
AU  - Tokuhei Ikeda
AU  - Kenjiro Ono
PY  - 2026
JO  - The Journal of Prevention of Alzheimer's Disease
DO  - 10.1016/j.tjpad.2026.100668
UR  - https://doi.org/10.1016/j.tjpad.2026.100668
ER  - 

APA

Noguchi-Shinohara, M., Muramatsu, D., Shima, A., Sakashita, Y., Tada, Y., Yamaguchi, H., Komatsu, J., Ikeda, T., & Ono, K. (2026). Corrigendum to “Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181” [The Journal of Prevention of Alzheimer's Disease (2026) 100664]. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2026.100668

Source records